These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Attachment of tumor cells to endothelial monolayers: detection of surface molecules involved in cell-cell binding.
    Author: Antonia SJ, Uchida J, Cohen S, Cohen MC.
    Journal: Clin Immunol Immunopathol; 1989 Nov; 53(2 Pt 1):281-96. PubMed ID: 2676274.
    Abstract:
    Trypsinization of P815 mastocytoma cells interferes with their ability to bind to endothelial monolayers in vitro, suggesting the involvement of proteins in cell-cell binding. Binding is also dependent upon divalent cations. Incubation of tumor cells with tunicamycin, which blocks protein glycosylation, or the monosaccharide N-acetyl-D-glucosamine could also inhibit binding. In addition, antibodies prepared against whole P815 cells had the ability to interfere with tumor cell binding. The protein fragments released from P815 cells by trypsin interfered with the binding of fresh P815 cells to endothelium. Moreover, those fragments as well as CHAPS extracts of tumor cell membranes were able to neutralize the inhibitory effect of an anti-P815 antibody on tumor cell-endothelial cell binding. These observations, taken together, strongly suggest the presence of adhesion molecules on the tumor cell. The anti-P815 antibody preparation could also inhibit endothelial binding of an unrelated tumor. Ehrlich ascites (EA). In addition, membrane preparations of EA could neutralize the antibody's effect on intact P815, and membrane preparations of P815 could neutralize the antibody's effect on EA. These observations suggest that there are common epitopes on these tumor cells and raise the possibility that a variety of tumors may share common mechanisms for attachment to endothelium. This, in turn, raises the possibility that monospecific antibodies against such epitopes might be useful agents for interfering with metastasis in vivo.
    [Abstract] [Full Text] [Related] [New Search]